Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | PDE4A | P27815 | 2/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL313217 | 0.81 | LMNA (0.73) | MAPK1LMNAHTTRAB9AKMT2A | |
| SCHEMBL4817872 | 0.80 | HTT (0.63) | MAPK1LMNAHTTRAB9APDE4A | |
| SCHEMBL14451171 | 0.79 | KMT2A (0.60) | MAPK1LMNAHTTRAB9AKMT2A | |
| SCHEMBL1988161 | 0.76 | HTT (0.71) | MAPK1LMNAHTTRAB9AKMT2A | |
| SCHEMBL12822521 | 0.75 | KMT2A (0.50) | MAPK1LMNAHTTRAB9AKMT2A | |
| SCHEMBL6613832 | 0.75 | RAB9A (0.52) | MAPK1LMNAHTTRAB9AKMT2A | |
| SCHEMBL9970808 | 0.74 | KMT2A (0.53) | LMNARAB9AKMT2AMAPTALDH1A1 | |
| SCHEMBL863160 | 0.73 | MAPK1 (0.56) | MAPK1LMNARAB9AKMT2APDE4A | |
| SCHEMBL28217099 | 0.72 | HTT (0.76) | MAPK1LMNAHTTRAB9AKMT2A | |
| SCHEMBL9149352 | 0.72 | LMNA (0.60) | MAPK1LMNAHTTRAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163013-A1 | TREATMENT OF GENITOURINARY SYNDROME OF MENOPAUSE | NORDEEN, Steven | 2025-05-22 | — | — | US | disclosed |
| WO-2023147289-A1 | TREATMENT OF GENITOURINARY SYNDROME OF MENOPAUSE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163013-A1 | TREATMENT OF GENITOURINARY SYNDROME OF MENOPAUSE | SHBG, GSS, GPER1 | MAPK1 3949/4885LMNA 1724/4885HTT 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.